Business Description
Regeneron Pharmaceuticals is a New York-based company that researches, develops, and sells treatments for a wide range of serious health conditions, including eye diseases, cancer, heart disease, and rare disorders. Its portfolio includes well-known medicines such as EYLEA, Dupixent, Libtayo, Praluent, and Kevzara, which are used by patients around the world. The company works alongside partners like Bayer, Alnylam, and Intellia Therapeutics to advance next-generation therapies, including gene-editing and RNA-based treatments. Founded in 1988, Regeneron continues to grow its pipeline through both internal research and strategic licensing agreements.
